MoonLake Immunotherapeutics
MLTX
MLTX
43 hedge funds and large institutions have $843M invested in MoonLake Immunotherapeutics in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
3.85% more ownership
Funds ownership: 96.84% → 100.69% (+3.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Holders
43
Holding in Top 10
2
Calls
–
Puts
–
Top Buyers
| 1 | +$35.7M | |
| 2 | +$17.7M | |
| 3 | +$17.2M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.2M |
| 5 |
JPMorgan Chase & Co
New York
|
+$5.53M |
Top Sellers
| 1 | -$13.4M | |
| 2 | -$10.5M | |
| 3 | -$7.79M | |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$4M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$3.15M |